Article Sidebar

PDF
Date Published: 15/11/2023
Abstract Views: 92
Views PDF: 76
DOI: https://doi.org/10.51298/vmj.v531i2.7179
Issue
Vol. 531 No. 2 (2023)
Section
Các bài báo
How to Cite
Đỗ , A. T. ., & Nguyễn , Đình L. . (2023). OVERALL SURVIVAL OUTCOME IN METASTATIC PROSTATE CANCER TREATED WITH SEQUENTIAL ADT AND ADT PLUS ABIRATERONE ACETATE. Vietnam Medical Journal, 531(2). https://doi.org/10.51298/vmj.v531i2.7179

OVERALL SURVIVAL OUTCOME IN METASTATIC PROSTATE CANCER TREATED WITH SEQUENTIAL ADT AND ADT PLUS ABIRATERONE ACETATE

Anh Tú Đỗ 1,, Đình Lợi Nguyễn 2
1 k hospital
2 HMU

Main Article Content

Abstract

Background: Our study evaluated the overall survival of patients with metastatic prostate cancer (mPCa) receiving sequential ADT and ADT plus Abiraterone acetate (AAP). Methods: This retrospective, observational study collected data from chemotherapy-naïve mCRPC patients treated with AAP in Vietnam National cancer hospital. Kaplan-Meier curves were used to estimate time overall survival (OS). The impact of baseline characteristics on OS was explored using univariate and multivariate Cox proportional hazard models. Results: Data from 65 eligible patients were analyzed. The median age was 67 years (interquartile range [IQR]: 62–74). The rate of patients de novo was 75,4%, Gleason ≥ 8 was 78,5%, and ECOG PS ≥ 2 was 24,6%. The rate of patients with high burden was 46,2%. The median PSA was 150,6 ng/ml (IQR: 41,6-292,2). The median overall survival was 44,5 months (95% CI: 37,5-51,5) and the 5-year survival rate was 20%. Age (≥ 70), ECOG PS (PS ≥ 2), Gleason score (≥ 8), de novo were factors with independent prognostic value for OS (p < 0,05). Conclusion: The median overall survival was 44,5 months (95% CI: 37,5-51,5) and the 5-year survival rate was 20%.

Article Details

Keywords

Metastatic prostate cancer (mPCa), ADT, ADT plus Abiraterone acetate, overall survival

References

1. Cancer today. , accessed: 05/08/2023.
2. Cancer of the Prostate - Cancer Stat Facts. SEER, , accessed: 05/08/2023.
3. Ryan C.J., Smith M.R., De Bono J.S. và cộng sự. (2013). Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med, 368(2), 138–148.
4. James N.D., Clarke N.W., Cook A. và cộng sự. (2022). Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). Int J Cancer, 151(3), 422–434.
5. Humphreys M.R., Fernandes K.A., và Sridhar S.S. (2013). Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC). J Cancer, 4(4), 304–314.
6. Sweeney C.J., Chen Y.-H., Carducci M. và cộng sự. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med, 373(8), 737–746.
7. Koura M., Shiota M., Ueda S. và cộng sự. (2021). Prognostic impact of prior local therapy in castration-resistant prostate cancer. Jpn J Clin Oncol, 51(7), 1142–1148.
8. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design - The Lancet.